Humanin is a small peptide (21 amino acids) encoded within the mitochondrial genome — specifically within the 16S rRNA gene. Discovered in 2001 by Nishimoto and colleagues in the context of Alzheimer's disease research, Humanin has since been found to circulate naturally in blood and tissue, with circulating levels declining with age. It has shown protective effects in models of Alzheimer's disease, cardiovascular disease, metabolic dysfunction, and general cellular stress — making it one of the more intriguing mitochondrial-derived peptides in longevity research.
Research context only. The peptides and compounds discussed on WolveStack are research chemicals not approved for human use by the FDA. Nothing on this page constitutes medical advice. Consult a qualified healthcare professional before use.
Humanin is a 21-amino acid peptide encoded within the mitochondrial genome that circulates naturally in blood and tissue. It functions as a cytoprotective signal, protecting cells from apoptosis under stress conditions. Circulating levels decline with age.
How Does Humanin Work?
Humanin appears to function as a cytoprotective signalling peptide — its primary role seems to be protecting cells from apoptosis (programmed cell death) under conditions of stress. It was originally identified by its ability to protect neurons from Alzheimer's disease-associated toxicity, including amyloid-beta and other insults.
Several receptors have been identified for Humanin, including formyl peptide receptor-like 1 (FPRL1/FPR2), gp130 (a component of IL-6 receptor complexes), and TrkA. The receptor binding diversity suggests Humanin acts through multiple signalling pathways simultaneously.
Metabolically, Humanin improves insulin sensitivity and glucose tolerance in animal models — it appears to sensitise cells to insulin signalling, making it interesting for metabolic aging research. Cardiovascular effects include protection from ischemia-reperfusion injury and reduced oxidative stress in cardiac tissue.
What the Research Shows
Humanin research has accelerated since its initial discovery, with key findings in multiple disease models:
In Alzheimer's models, Humanin consistently protects neurons from amyloid-beta toxicity, oxidative stress, and mitochondrial dysfunction. Whether this translates to meaningful therapeutic benefit in human AD is being actively studied.
In cardiovascular research, Humanin has shown protection from ischemia-reperfusion injury in heart and brain, reduced atherosclerosis progression, and improved cardiac function in stress models.
In metabolic research, Humanin improves insulin sensitivity, reduces hepatic glucose output, and shows beneficial effects on body composition in obese animal models.
Perhaps most relevant to longevity: circulating Humanin levels have been correlated with longevity in human centenarian studies. Children of centenarians have higher Humanin levels than age-matched controls whose parents were not long-lived — suggesting Humanin as a potential biomarker and mediator of longevity.
Research Protocol Reference
| Form | Dose | Route | Frequency | Notes |
|---|---|---|---|---|
| Humanin-G (S14G-Humanin) | 1–3 mg/day | SubQ | Daily | More potent analog, most common |
| Native Humanin | 3–5 mg/day | SubQ | Daily | Less potent than S14G form |
| Longevity protocol | 1 mg/day | SubQ | Daily or 5 on/2 off | Conservative maintenance |
Safety and Current Evidence Status
Humanin has a strong safety profile in animal research with no significant adverse effects documented at research doses. Human data is limited — it is not yet in clinical trials and the community research experience is more limited than for peptides like BPC-157 or TB-500.
**S14G-Humanin (Humanin-G)** is the most commonly used form in research protocols — a single amino acid substitution (Ser to Gly at position 14) that increases potency approximately 1000-fold. Most community protocols use the S14G form rather than native Humanin for this reason.
**Evidence quality caveat:** Humanin's research base is primarily preclinical. The longevity correlations in human data are observational. Whether exogenous Humanin supplementation replicates the biological significance of endogenously high Humanin in long-lived individuals is not yet established.
**Stacking:** Commonly paired with MOTS-c in longevity protocols — both are mitochondrial-derived peptides with complementary metabolic effects. The combination is sometimes called the "mito-peptide stack" in longevity research communities.
Research-Grade Sourcing
WolveStack partners with Ascension Peptides for independently third-party tested research compounds with published COAs. The links below go directly to the relevant products.
For research purposes only. Affiliate disclosure: WolveStack earns a commission on qualifying purchases at no additional cost to you.
Also Available at Apollo Peptide Sciences
Apollo Peptide Sciences carries independently tested research-grade compounds. Products ship from the USA with published purity certificates.
For research purposes only. Affiliate disclosure: WolveStack earns a commission on qualifying purchases at no additional cost to you.
Frequently Asked Questions
Humanin is a 21-amino acid peptide encoded within the mitochondrial genome that circulates naturally in blood and tissue. It functions as a cytoprotective signal, protecting cells from apoptosis under stress conditions. Circulating levels decline with age. It has shown protective effects in Alzheimer's, cardiovascular, and metabolic disease models, and correlates with longevity in human studies.
S14G-Humanin (Humanin-G) is a synthetic analog with a serine-to-glycine substitution at position 14, making it approximately 1000 times more potent than native Humanin. It is the preferred form for research protocols because lower doses achieve equivalent biological activity. Most community protocols use S14G-Humanin rather than native Humanin.
Humanin appears to protect cells from age-related stresses — mitochondrial dysfunction, oxidative damage, amyloid toxicity, and insulin resistance. Its correlation with longevity in centenarian studies suggests it may be a mediator or marker of healthy aging. Research protocols hypothesise that maintaining or supplementing Humanin levels may slow age-related cellular decline, though human intervention data is limited.
Preclinical evidence is consistently positive — Humanin protects neurons from multiple Alzheimer's-associated insults including amyloid-beta toxicity and oxidative stress. No clinical trials in Alzheimer's patients have been completed yet. It remains a research-stage interest rather than an established treatment.
Yes — Humanin is commonly stacked with MOTS-c (another mitochondrial peptide with metabolic effects), GHK-Cu (collagen synthesis, antioxidant), and Epithalon (telomere biology, pineal function). The combination addresses multiple aging mechanisms simultaneously.
Humanin is encoded within the 16S rRNA gene of the mitochondrial genome — the same mitochondrial DNA inherited maternally and present in essentially all cells. It's part of a class of small proteins called mitochondrial-derived peptides (MDPs). Its discovery confirmed that mitochondria encode functional proteins beyond those directly involved in ATP production.